QIAGEN Showcases Integrated Sample-to-Insight Oncology Solutions at AACR 2026

At the American Association for Cancer Research (AACR) Annual Meeting 2026, QIAGEN is presenting an expanded portfolio of Sample-to-Insight solutions designed to streamline oncology workflows from sample preparation through multi-omics analysis and data interpretation. The showcase highlights integrated technologies aimed at improving reproducibility, scalability, and insight generation in cancer research and molecular diagnostics.

Held April 17–22 in San Diego, AACR 2026 brings together researchers, clinicians, and industry leaders to explore advances in cancer biology, diagnostics, and therapeutic development. At the meeting, QIAGEN is demonstrating how its end-to-end workflow approach addresses persistent challenges such as fragmented processes, variability in sample handling, and the growing complexity of multi-omics datasets.

Image: QIAGEN is showcasing QIAsymphony Connect at AACR 2026 among other solutions addressing key oncology research needs (phot courtesy of Qiagen)

Central to the exhibit is the upcoming QIAsymphony Connect system, an evolution of the company’s established automation platform for molecular testing. Designed to support oncology applications, the system enables automated sample extraction with enhanced traceability, process safety, and throughput, while delivering high-quality nucleic acids for sensitive downstream assays. The platform aims to reduce hands-on time and standardize workflows across laboratories.

QIAGEN is also highlighting the QIAsprint Connect, a compact high-throughput automation platform for research laboratories capable of processing up to 192 DNA or RNA samples per run. The system supports customizable workflows and is designed to scale sample processing while reducing consumable use and laboratory waste.

In the area of single-cell analysis, the company is presenting the Evercode Whole Transcriptome portfolio from its Parse Biosciences subsidiary. This includes a newly introduced version offering improved cell recovery, higher sensitivity, and shorter workflows, as well as a kit for formalin-fixed paraffin-embedded (FFPE) samples. These tools are intended to expand access to high-resolution transcriptomic profiling in oncology research.

Also being presented, the QIAseq xHYB Trinity DNA/RNA Kit enables comprehensive genomic profiling from DNA, RNA, or both within a single workflow using the Element Biosciences AVITI platform. Designed for streamlined target enrichment, the kit reduces hybridization time, minimizes manual cleanup steps, and eliminates post-enrichment PCR, supporting efficient workflows and reliable variant detection in research settings.

Across these solutions, QIAGEN emphasizes integration of sample technologies with genomic profiling and bioinformatics interpretation, enabling researchers to move more efficiently from biological samples to actionable insights. By linking automation, sequencing workflows, and data analytics, the company aims to support more consistent and reproducible results in increasingly complex oncology applications.

“Cancer research and molecular diagnostics are increasingly constrained by fragmented workflows, variability in sample processing and the growing complexity of multi-omics data,” said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN. “At AACR, we are demonstrating how QIAGEN’s Sample to Insight portfolio helps standardize critical steps from sample preparation through data interpretation, enabling more consistent results, improved reproducibility and more confident insights from complex biological data.”